Diffuse Large B Cell Lymphoma

P3, N=400, Recruiting, Lyell Immunopharma, Inc. | Not yet recruiting --> Recruiting

P=N/A, N=100, Recruiting, Medical University of Gdansk

P1/2, N=20, Not yet recruiting, Seoul National University Hospital

P1, N=40, Recruiting, University Health Network, Toronto | Trial completion date: Jun 2027 --> Sep 2027 | Trial primary completion date: Jun 2025 --> Sep 2027

P2, N=152, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting

P1, N=340, Recruiting, AbbVie | N=244 --> 340

Finally, we reveal that macrophages enhance tumor cell proliferation and promote resistance to doxorubicin in co-culture. In conclusion, these results confirm the robustness of this model to study lymphoma cell and macrophage interplays, underline the critical role of IL-10 in lymphoma microenvironment modeling, and may contribute to better define its specificities in an era of rising microenvironment-targeted therapies.

Correlations showed Enterobacteriaceae positively linked to Th cells/PCT/TNF and negatively to IL-10 in small B-cell lymphoma; Actinobacteriota correlated with B/T cells/Treg/IFN-β and inversely with IL-2/IL-4/CD8+T cells. This study identifies distinct patterns of gut microbiota dysbiosis across B-cell lymphoma subtypes and explores their correlations with host immune parameters.

This case demonstrates the diagnostic complexities of PTL with gonadal vein tumor thrombus, underscoring the importance of considering lymphoma in elderly patients with testicular masses and venous involvement. A multi-disciplinary team including urologists, hematologists, and radiation oncologists is needed to ensure appropriate therapy.

Although the R-CHOP regimen effectively cures 60-70% of patients, 30-40% of patients relapse or develop resistance, highlighting the need for new biomarkers to improve prognosis and therapeutic strategies...Our findings suggest that the SREBF2-ACOT7 axis plays a critical role in DLBCL by promoting tumor cell growth, invasion, and survival. ACOT7 could serve as a potential prognostic biomarker and therapeutic target for DLBCL, providing new insights into the molecular mechanisms of this aggressive lymphoma.

The clinical course was aggressive, and the patient died of the disease on the 13th day of hospitalization. This case highlights the potential for aggressive T-cell lymphoma to emerge during bispecific antibody therapy, a phenomenon that has also been noted in the context of CAR-T cell therapy.

Moreover, dysregulation of ZCCHC8 occurs frequently in diffuse large B cell lymphoma (DLBCL) and is associated with poor clinical outcomes. Collectively, our findings highlight NEXT as a novel protector of HSCs and position it as a potential therapeutic target for DLBCL.